Pfizer announced on Monday that its COVID-19 vaccine with BioNTech was found to be more than 90% effective in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.
In Latin America, Chile, Mexico and Ecuador had signed a purchase agreement with Pfizer and BioNtech, and the pharmaceutical firms are conducting trials in Argentina and Brazil.
Albert Bourla, Pfizer’s chairman and chief executive said in a statement that the results demonstrate that Pfizer’s mRNA-based vaccine can help prevent COVID-19 in the majority of people who receive it. “This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic, “he said.
However, according to Bourla, it is not possible to apply for the American Food and Drug Administration (FDA) Emergency Use Authorization based on these efficacy results alone. “More data on safety is also needed, and we are continuing to accumulate that safety data as part of our ongoing clinical study.”